COVID-19

  • Triangular-shaped spikes key to coronavirus transmission
    16 April 2021

    Triangular-shaped spikes key to coronavirus transmission, finds new study

    COVID-19 needs no introduction. Last year, the disease, which is caused by the virus SARS-CoV-2, reached every continent across the globe. By the end of March 2021, there had been an estimated 128 million cases recorded with almost three million of these being fatal. As scientists' race to develop vaccines and politicians coordinate their distribution, fundamental research on what makes this virus so successful is also being carried out.

  • 15 April 2021
    The sequence of pfizer & moderna mRNA COVID19 vaccines decoded by Stanford scientists and posted on github

    Stanford scientists saved drops of the COVID-19 vaccine destined for the garbage can, reverse engineered them, and have posted the mRNA sequence that powers the vaccine on GitHub for all to see.

  • 14 April 2021
    Vacancy for Pharmacist at Jalgaon Municipal Corporation

    Jalgaon Municipal Corporation was founded in 21 march. 2003 & Smt.Ashatai Kolhe has become a first Leady Mayor of Jalgaon Municipal Corporation History. Jalgaon Municipal Corporation serves an area approximately 68.78 Sq.km. & provides civil services & facilities around the 4.60 Lacks people.

  • 14 April 2021
    Tika Utsav is pivotal because we know that there is no proven medicine to combat COVID-19

    Tika Utsav is pivotal because we know that there is no proven medicine to combat COVID-19. We need to maintain 6 feet social distancing, wear the mask, regular hand washing, and regular sanitization, maintain a good diet and fitness, mentioned Dr. Manoj Nesari, Adviser (Ay.) Ministry of AYUSH, Govt. of India in the webinar organized by PHD Chamber of Commerce and Industry on Importance of TikaUtsav-Covid Vaccination.

  • 13 April 2021
    Dr. Reddys Laboratories Gets Emergency Use Authorisation for Sputnik V in India

    Dr. Reddys Laboratories Ltd announced that it has received the permission from the Drug Controller General of India(DCGI)to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clincial Trials rules, 2019 under the Drugs and Cosmetics Act.

  • 9 April 2021
    NIH begins study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines

    A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of the body beyond the injection site.

  • 8 April 2021
    Bioflavonoids Used in Citrobioshield Effectively Control Coronavirus in ICU and Wards

    The fresh surge in COVID-19 cases has now confirmed that the second wave of the coronavirus pandemic is here and is expanding its footprints in India. The study by the Centre for Cellular and Molecular Biology (CCMB) and CSIR-Institute of Microbial Technology (I M Tech) proved the presence of Coronavirus in air samples in Covid-19 wards of hospitals.

  • 8 April 2021
    AstraZeneca vaccine unlikely to cause blood clots, says MHRA

    Updated information is being provided for people and healthcare professionals on the possible risk of extremely rare and unlikely to occur specific types of blood clots following vaccination with the COVID-19 Vaccine AstraZeneca, the Medicines and Healthcare products Regulatory Agency (MHRA) said.

  • 6 April 2021
    AstraZeneca Covid-19 vaccine show 79% efficacy against symptomatic and 100% efficacy against severe disease

    The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had a 2:1 randomisation of vaccine to placebo. Vaccine efficacy was consistent across ethnicity and age. Notably, in participants aged 65 years and over, vaccine efficacy was 80%.

  • 5 April 2021
    Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in COVID-19

    Zydus Cadila announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b, PegiHepTM has shown promising results in treating COVID-19. In what could be a breakthrough in the disease management of COVID-19, the interim results indicate that PegIFN when administered early on, could help patients recover faster and avoiding much of the complications seen in the advanced stages of the disease. PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents.

Subscribe to COVID-19